Page 43 - AN-2-1

Advanced Neurology

REVIEW ARTICLE
Treatment of Parkinson’s disease with

piribedil: Suggestions for clinical practices

Cheng Jie Mao , Chan Piu , Li Rong Jin , Li Juan Wang , Olivier Rascol *, and
2
1
5
4
3
Chun Feng Liu *
1
1 Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou 215000,
Jiangsu, China
2 Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing 100053, China
3 Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
4 Department of Neurology, Guangdong Provincial Peoples’ Hospital, Guangzhou 510080,
Guangdong, China
5 Clinical Investigation Center CIC1436, Departments of Clinical Pharmacology and Neurosciences,
NS-Park/FCRIN network and NeuroToul Center of Excellence for Neurodegeneration, INSERM,
University Hospital of Toulouse and University of Toulouse, Toulouse, France

Abstract
With rapidly growing rates of prevalence, disability, and mortality, Parkinson’s disease
(PD) has become a global healthcare burden. Increasing elderly population increases
the incidence of neurodegenerative diseases in China. Hence, PD poses a huge
burden to Chinese economic and healthcare system. PD is a movement disorder
that affects the motor and nonmotor functions. Dopamine agonists are used in the
*Corresponding authors: management of PD. Piribedil is an antiparkinsonian drug and piperazine derivative,
Olivier Rascol
(olivier.rascol@univ-tlse3.fr) which acts as D2/D3 receptor agonist. Piribedil is one of the non-ergot dopamine
Chun Feng Liu receptor (DR) agonists and has been used in China for many years as monotherapy
(liuchunfeng@suda.edu.cn) or in combination with levodopa. In this paper, we present a review of clinical
Citation: Mao CJ, Piu C, Jin LR, application of piribedil, management of adverse events, and drug interactions, and
et al., 2023, Treatment of discuss the results of clinical trials of piribedil on motor and non-motor symptoms
Parkinson’s disease with piribedil: of PD.
Suggestions for clinical practices.
Adv Neuro, 2(1): 290.
https://doi.org/10.36922/an.290
Keywords: Neurodegenerative disease; Levodopa; Dopamine receptor; Non-ergot
Received: December 14, 2022 dopamine receptor agonists; α2-adrenoreceptor; Dyskinesia; Hypotension orthostatic
Accepted: January 16, 2023
Published Online: February 10,
2023 1. Introduction
Copyright: © 2023 Author(s).
This is an Open Access article Parkinson’s disease (PD) is the second most common neurodegenerative disease after
distributed under the terms of the Alzheimer’s disease . PD affects 41 and 107 persons/100,000 people who were in the
[1]
Creative Commons Attribution
[2]
License, permitting distribution, fourth and fifth decade of age, respectively . It affects 1903 persons/100,000 people who
and reproduction in any medium, were aged above 80 years, with peak age group between 85 and 89 years .
[3]
provided the original work is
properly cited. According to the reports of Global Burden of Disease Study 2016, the prevalence of
Publisher’s Note: AccScience patients with PD in 2016 was approximately 6.10 million in 2016 compared with 2.50
Publishing remains neutral with million in 1990. China reports a higher rate of incidence of PD compared with the rest
regard to jurisdictional claims in
published maps and institutional of the world. The prevalence of PD is higher in men (52.5%) than in women (47.5%).
affiliations. It is estimated that in China, nearly 23.9 – 26.9% of the population will be aged above

Volume 2 Issue 1 (2023) 1 https://doi.org/10.36922/an.290